NVIDIA CORP

• MEDStock-based compensation was $6.4B in FY2026, up 35% from $4.7B in FY2025, and represents approximately 3% of total revenue S5. Unearned SBC of $14.8B remains to be expensed over roughly 2.3 years (RSUs and PSUs) and 0.9 years (ESPP) S6. There are 1.3B shares available for future grants under equity incentive plans and 2.2B shares reserved under the ESPP S6. The Groq acquisition and any future M&A could involve dilutive equity issuances S3. While share repurchases of $40.4B in FY2026 (282M shares retired) partially offset this, the $14.8B unearned SBC pipeline is large in absolute dollars S5S6.

Nothing flagged.

• LOWTotal debt is $8.5B in senior notes with maturities through 2060; $999M is due within

• HIGHTwo direct customers accounted for 22% and 14% of total FY2026 revenue respectively, up from 12%, 11%, and 11% for the top three customers in FY2025 S3S4S6. Three direct customers represented 25%, 18%, and 13% of accounts receivable as of January 25, 2026 S6. Some indirect customers individually represent 10% or more of revenue S3. The filing notes that one AI research and deployment company represents a "meaningful amount" of revenue through cloud services S4. Most sales are on purchase order basis with no penalties for cancellation, change, or delay S3. This degree of revenue concentration at the top of a parabolic growth curve, with no contractual lock-in, is a material risk if any single hyperscaler cuts or delays orders.
• MEDNVIDIA is a fabless company with primary manufacturing dependence on TSMC and Samsung, and a single-source dependency for CoWoS advanced packaging S1S2. Memory supply depends on SK Hynix, Micron, and Samsung S1. Approximately 6,000 employees (roughly 14% of total headcount) are based in Israel working on R&D, operations, and sales for networking products; extended military duty has already caused limited disruption S3. Any escalation in the Israel conflict, TSMC disruption (including Taiwan geopolitical risk), or CoWoS bottleneck could directly delay product shipments.

• MEDCFO Colette Kress adopted a Rule 10b5-1 plan on December 18, 2025 to sell 500,000 shares by March 23, 2027 S5. While planned sales under 10b5-1 are not inherently alarming, the scale (500,000 shares) is notable. NVIDIA is also finalizing an investment and partnership agreement with OpenAI, with the filing explicitly stating "no assurance" the transaction will complete S3S4, and has committed $3.5B in facility lease guarantees to early-stage partner companies over 5 to 7 year terms, with only $712M held in escrow as mitigation S6. These represent related-party and counterparty risks that are not fully transparent.

• MEDGross margin declined to 71.1% in FY2026 from 75.0% in FY2025 S4S5, driven by business model transition costs and the H20 inventory charge. Named competitors include AMD, Intel, Huawei, Amazon, Microsoft, Alibaba, and Baidu, with cloud service companies actively developing internal AI accelerators that compete directly with NVIDIA products S2. Export controls have encouraged customers to "design out" U.S. semiconductors and are helping competitors build larger developer and customer ecosystems in China S2S3. NVIDIA patents expire between March 2026 and June 2045, and IP protections are described as weaker in Asian jurisdictions S2. The Rubin platform is not shipping until H2 FY2027 S1, creating a window for competitors to close the gap on Blackwell.

• HIGHTotal inventory jumped to $21.4B (from $10.1B the prior year), and NVIDIA holds $95.2B in outstanding manufacturing and supply commitments that are substantially due in FY2027, plus $27B in multi-year cloud service commitments S5S6. Inventory provisions reached $4.0B in FY2026 (versus $3.7B total in FY2025), and excess purchase obligations account for $2.7B of that S4S6. The external auditor flagged inventory valuation as a "critical audit matter," citing significant management judgment required on demand assumptions and the impact of export restrictions S5. Low-yielding Blackwell material negatively impacted gross margins in Q2 FY2025, and supply constraints are expected to be a headwind to Gaming in Q1 FY2027 and beyond S2. NVIDIA places non-cancellable orders with lead times exceeding 12 months S2S4, meaning a demand slowdown or additional export restriction could crystallize large new writedowns quickly.
• MEDNVIDIA spent $13.0B at closing in December 2025 to acquire Groq Inc., recording $14.4B in goodwill and $2.5B in developed technology intangibles, with an additional $4.0B payable within one year now sitting in current liabilities S5. No customer contracts or existing products were acquired, only licensed technology and employees S5. Total goodwill is now $20.8B, up $15.6B in FY2026 S6. Paying $17B for technology with no revenue base and no contracted customers, in an environment where AI chip competition is accelerating, creates real impairment risk. Separately, NVIDIA is implementing a new ERP system, which the filing flags as a risk to operations and financial reporting S3.

• HIGHThe U.S. government imposed export license requirements on H20 chips to China in April 2025, triggering a $4.5B inventory charge in Q1 FY2026 and generating only $60M in H20 revenue under limited August 2025 licenses S2S3S4. NVIDIA is now effectively foreclosed from China's data center market, which was a material revenue opportunity. A February 2026 license covers only small H200 shipments to specific China customers and subjects those shipments to a 25% tariff S3S4. Separately, China's antitrust regulators found in September 2025 that NVIDIA's export-control-driven product decisions violated Mellanox acquisition approval terms, creating potential penalties and restrictions on the networking business S3. A proposed worldwide AI Diffusion rule covering H200 and GB200 was announced in January 2025, then rescinded in May 2025, but a replacement rule is still pending with unknown scope S2S3. NVIDIA states it cannot create a product that satisfies both U.S. export rules and Chinese government approval simultaneously S2. The combination of lost China revenue, the $4.5B writedown, ongoing regulatory uncertainty, and the antitrust finding represents a compounding, open-ended threat.

• MEDMultiple securities class action and derivative lawsuits are pending related to alleged false or misleading statements about channel inventory and cryptocurrency mining demand in 2017 to 2018 S4S6. The Supreme Court dismissed NVIDIA's certiorari petition on December 11, 2024, and the case was remanded to district court on February 20, 2025 S6. No liability has been accrued because management does not consider an adverse outcome probable, but the case is now actively proceeding at the district court level S6. Additionally, EU, U.S., UK, China, and South Korea competition regulators have all issued broad information requests regarding GPU sales, supply allocation, foundation models, investments, and partnerships S3.

• MEDUnrecognized tax benefits total $4.4B, with NVIDIA subject to IRS examination for FY2023 and FY2024 S4S6. A valuation allowance of $768M has been established on deferred tax assets S6. GDPR penalties could reach up to 4% of worldwide revenue (on $215.9B revenue that is a theoretical maximum exposure of approximately $8.6B) S4. The OECD Two-Pillar framework is increasing compliance costs, and the FDDEI deduction may be reduced, which would increase the effective tax rate S4.